REGENXBIO Inc. (NASDAQ:RGNX) had its price objective increased by Chardan Capital from $75.00 to $85.00 in a research note published on Thursday morning, Marketbeat reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued research reports about the company. BidaskClub upgraded REGENXBIO from a hold rating to a buy rating in a research note on Saturday, August 12th. Zacks Investment Research upgraded REGENXBIO from a hold rating to a buy rating and set a $23.00 target price for the company in a research note on Saturday, August 12th. Evercore ISI began coverage on REGENXBIO in a research note on Wednesday, August 16th. They set an outperform rating and a $25.00 target price for the company. Bank of America Corporation boosted their target price on REGENXBIO from $29.00 to $33.00 and gave the stock a buy rating in a research note on Thursday, September 21st. Finally, Raymond James Financial, Inc. began coverage on REGENXBIO in a research note on Thursday, October 12th. They set an outperform rating and a $39.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $40.57.
Shares of REGENXBIO (NASDAQ:RGNX) traded up $0.70 on Thursday, hitting $27.50. The stock had a trading volume of 238,500 shares, compared to its average volume of 330,076. REGENXBIO has a fifty-two week low of $16.30 and a fifty-two week high of $36.10.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.04. The business had revenue of $1.34 million during the quarter. REGENXBIO had a negative return on equity of 39.33% and a negative net margin of 764.06%. sell-side analysts expect that REGENXBIO will post -2.63 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Chardan Capital Increases REGENXBIO Inc. (RGNX) Price Target to $85.00” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/13/chardan-capital-increases-regenxbio-inc-rgnx-price-target-to-85-00.html.
In other REGENXBIO news, insider Stephen Yoo sold 32,658 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $25.00, for a total value of $816,450.00. Following the completion of the sale, the insider now owns 31,803 shares in the company, valued at $795,075. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Vittal Vasista sold 3,040 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $21.09, for a total value of $64,113.60. Following the completion of the sale, the chief financial officer now owns 103,118 shares of the company’s stock, valued at approximately $2,174,758.62. The disclosure for this sale can be found here. In the last quarter, insiders sold 210,040 shares of company stock valued at $5,874,639. 17.00% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in RGNX. State Street Corp increased its holdings in shares of REGENXBIO by 178.1% in the second quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock valued at $17,399,000 after purchasing an additional 564,129 shares during the period. GMT Capital Corp increased its holdings in shares of REGENXBIO by 1,086.2% in the second quarter. GMT Capital Corp now owns 609,700 shares of the biotechnology company’s stock valued at $12,346,000 after purchasing an additional 558,300 shares during the period. Redmile Group LLC increased its holdings in shares of REGENXBIO by 35.4% in the second quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock valued at $33,944,000 after purchasing an additional 449,540 shares during the period. Citadel Advisors LLC increased its holdings in shares of REGENXBIO by 65.4% in the second quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock valued at $18,292,000 after purchasing an additional 366,289 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of REGENXBIO by 23.2% in the first quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock valued at $18,942,000 after purchasing an additional 184,700 shares during the period. 73.13% of the stock is currently owned by institutional investors and hedge funds.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.